FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer By Ogkologos - June 27, 2025 489 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ARANOTE study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR New Treatments for Non-Small Cell Lung Cancer With an EGFR Mutation:... December 16, 2021 Studies Provide First Evidence That Breastfeeding after Breast Cancer Is Safe September 8, 2024 ‘Scandinavian quality and Singaporean efficiency’: what the autumn statement means for... November 17, 2022 Pump Up the Volume: “Priming Agents” May Improve Cancer Liquid Biopsies February 22, 2024 Load more HOT NEWS Working Outdoors in the Sunshine May Lower Your Risk of Breast... Crazy Bride Called Off Her Wedding Because Her Guests Refused To... FDA Approves Avapritinib for Advanced Systemic Mastocytosis Dad With Cancer Escorts His Autistic Son To School, With The...
